This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
RDUS Overzicht aandelen
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 2/6 |
| Dividenden | 0/6 |
Radius Health, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$10.10 |
| 52 Week Hoogtepunt | US$23.00 |
| 52 Week Laag | US$4.97 |
| Bèta | 0.52 |
| 11 maand verandering | -0.39% |
| 3 maanden verandering | 78.76% |
| 1 Jaar Verandering | -27.08% |
| 33 jaar verandering | -55.21% |
| 5 jaar verandering | -71.49% |
| Verandering sinds IPO | 26.09% |
Recent nieuws en updates
Radius Recycling Stays In The Scrap Pile
Jul 16Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future
Jun 03Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype
Aug 11Recent updates
Radius Recycling Stays In The Scrap Pile
Jul 16Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future
Jun 03Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype
Aug 11Reevaluating Radius Health
Feb 24Radius Health EPS misses by $0.02, misses on revenue
May 07When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?
Feb 23
Revisiting Radius Health
Feb 01Radius Health acquires global rights to RAD011 in Prader-Willi syndrome
Jan 06How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?
Jan 01
Radius Health on-track for record quarterly revenue for TYMLOS-SC
Dec 15Rendement voor aandeelhouders
| RDUS | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -0.1% | -0.2% | -0.4% |
| 1Y | -27.1% | 22.1% | 34.1% |
Rendement versus industrie: RDUS underperformed the US Biotechs industry which returned -22.1% over the past year.
Rendement versus markt: RDUS underperformed the US Market which returned -11.6% over the past year.
Prijsvolatiliteit
| RDUS volatility | |
|---|---|
| RDUS Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: RDUS's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: RDUS's weekly volatility (10%) has been stable over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2003 | 293 | G. Martin | radiuspharm.com |
Radius Health, Inc. Samenvatting
| RDUS fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$480.77m |
| Inkomsten(TTM) | -US$68.63m |
| Inkomsten(TTM) | US$223.36m |
2.2x
P/S-verhouding-7.0x
Koers/WinstverhoudingIs RDUS overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| RDUS resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$223.36m |
| Kosten van inkomsten | US$19.47m |
| Brutowinst | US$203.89m |
| Overige uitgaven | US$272.52m |
| Inkomsten | -US$68.63m |
Laatst gerapporteerde inkomsten
Jun 30, 2022
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -1.44 |
| Brutomarge | 91.28% |
| Nettowinstmarge | -30.72% |
| Schuld/Eigen Vermogen Verhouding | -124.2% |
Hoe presteerde RDUS op de lange termijn?
Bekijk historische prestaties en vergelijking